NEW YORK, Sept. 9, 2014 /PRNewswire/ -- Wolf Popper
LLP, lead counsel in the In re Amarin Corp. plc Securities
Litigation, pending in the U.S. District Court for the District of
New Jersey (Civil Action No.
13-cv-06663), is scheduled to file an amended complaint in the
class action on September 19,
2014. That complaint will assert claims against Amarin and
individual defendants arising out of the federal securities
laws. The allegations in the action relate to defendants'
alleged misrepresentations with respect to prospects for FDA
approval of Amarin's Vascepa drug for the ANCHOR indication.
On July 8, 2013, Amarin filed a
Prospectus Supplement for the issuance of 21.7 million American
Depositary Shares (ADSs) through underwriters Citigroup Global
Markets Inc. and Jefferies LLC. Investors who purchased
Amarin ADSs on the secondary offering through the underwriters on
or after July 9, 2013, are
specifically urged to contact Wolf Popper LLP to discuss their
legal rights to pursue claims in the amended complaint.
For more information, please contact:
Robert C. Finkel, Esq.
Tel.: 212.759.4600 or 877.370.7703 (toll free)
Fax: 212.486.2093 or 877.370.7704 (toll free)
Email:
irrep@wolfpopper.com
website:
www.wolfpopper.com
Attorney Advertising: Prior Results Do Not Guarantee A
Similar Outcome.
SOURCE Wolf Popper LLP